All News

Just as most public research bodies embrace commercialisation as their raison d'etre, the UK Medical Research Council is reversing the trend and taking a company it span out earlier back within its fold.

Charges of scientific fraud in Korea aren't likely to faze Britain's ambitious stem-cell efforts, as evidenced by plans for a £40 million lab run by the 'father' of Dolly the sheep.

Diamonds are the hardest natural substance known to man, and hard to find too. But Russian scientists say they have found a way to make prospecting for the precious mineral much easier.

"I didn't think they would be at this stage for decades, let alone within a year." Gerald Schatten, colleague of Korea's stem-cell celebrity, before scandal broke

At any given time over 1.4 million people worldwide are suffering from infections they got from their health-provider, according to the World Health Organization. Pelias AG, a newly created affiliate of Austrian biotech company Intercell AG, is hoping to raise €15 million to €20 million to make a dent in those numbers.

Forget stem cells, pharmacogenomics and the next big cure - Michael Kenward gazes into his prophecy book to see what the physical sciences have in store for us this year. Or maybe not.

European exchanges are opening back up for riskier ventures, and experts expect the trend to continue. But trade-sales should still dominate, says Mary Lisbeth D'Amico.

8.8 per cent: The proportion of GDP that OECD countries spend on health.

Cambridge University is tightening its grip on rights to intellectual property generated by staff and students after academics voted overwhelmingly to endorse new plans

Microsoft is to open more research centres in Europe, in a move to step up its research collaboration and boost students' interest in the technology field.

What are stem cells, what could they do - and why are investors wary of putting their money in them? A lay guide to the technology

Investing in technology that's a few years from commercialisation can be tricky. Lori Valigra finds out how some venture capitalists sort the wheat from the chaff.